Xencor | XNCR - Ebitda


Xencor reported $-51.05M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
AbbVie USD 3.52B 828M Sep/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amgen USD 5.14B 775M Dec/2025
Arrowhead Research USD 64.2M 223.53M Sep/2025
AstraZeneca USD 5.23B 272M Sep/2025
Biogen USD 573.2M 253.7M Dec/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Cytokinetics USD -277.18M 169.36M Sep/2025
GlaxoSmithKline GBP 3.36B 179M Sep/2025
J&J USD 9.52B 389M Sep/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
MacroGenics USD 21.95M 55.39M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Novartis USD 5.88B 290M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Xencor USD -51.05M 55.28M Dec/2025